News articles about InVitae (NYSE:NVTA) have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. InVitae earned a news impact score of 0.13 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 45.6802866755828 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several equities analysts recently weighed in on NVTA shares. BidaskClub raised shares of InVitae from a “hold” rating to a “buy” rating in a research report on Thursday, October 12th. Zacks Investment Research cut shares of InVitae from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Finally, Leerink Swann dropped their price target on shares of InVitae from $14.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $13.50.
InVitae (NYSE NVTA) opened at $9.10 on Friday. InVitae has a 1 year low of $2.60 and a 1 year high of $9.30. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.61 and a current ratio of 2.61. The company has a market cap of $488.68, a P/E ratio of -3.55 and a beta of 1.30.
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
What are top analysts saying about InVitae? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for InVitae and related companies.